| Zhou, Huan |
NCT06214143: A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 68 | RoW | T3011 high dose, T3011 middle dose, T3011 low dose | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Solid Tumors | 12/25 | 05/26 | | |
NCT04808648: The Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SH-1028 |
|
|
| Not yet recruiting | 1 | 40 | RoW | SH-1028, Itraconazole, Rifampicin | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Healthy Male Volunteers | 06/21 | 06/21 | | |
NCT04951713: Effect of Clarithromycin and Rifampicin on the Pharmacokinetics of XZP-3287 in Healthy Subjects |
|
|
| Recruiting | 1 | 60 | RoW | XZP-3287 combined with clarithromycin, XZP-3287 combined with rifampicin | Xuanzhu Biopharmaceutical Co., Ltd. | Healthy | 09/21 | 12/21 | | |
NCT04689100: Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor |
|
|
| Recruiting | 1 | 259 | RoW | JMT101, FOLFIRI(Irinotecan, Leucovorin Calcium, and Fluorouracil); mFOLFOX6((Oxaliplatin, Leucovorin Calcium, and Fluorouracil);, FOLFIRI; mFOLFOX6; Irinotecan; | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced Solid Tumor | 12/21 | 06/22 | | |
| Recruiting | 1 | 189 | RoW | KY-0118 | Novatim Immune Therapeutics (Zhejiang) Co., Ltd. | Neoplasms, Neoplasms by Histologic Type | 12/25 | 12/25 | | |
NCT06232863: A Study of BH009 in Head and Neck Squamous Cell Carcinoma and Ovarian Cancer |
|
|
| Recruiting | 1 | 24 | RoW | BH009 | Zhuhai Beihai Biotech Co., Ltd | Solid Tumor, Adult | 03/24 | 04/24 | | |
NCT06298071: A Phase Ib Clinical Trial of Peguricase for Injection With Methotrexate in Patients With Uncontrolled Gout. |
|
|
| Recruiting | 1 | 36 | RoW | SIBP-R002, Peguricase for injection, Methotrexate | Shanghai Institute Of Biological Products, First Affiliated Hospital Bengbu Medical College, The First Affiliated Hospital of Henan University of Science and Technology, Chengdu Fifth People's Hospital | Gout | 12/24 | 12/25 | | |
NCT05302388: A Study Exploring Efficacy of Pegloticase in Subjects With Asymptomatic Hyperuricemia |
|
|
| Completed | 1 | 45 | RoW | SIBP-R002, Dexamethasone or Methyl prednisolone, Diphenhydramine, Placebo | Shanghai Institute Of Biological Products, First Affiliated Hospital Bengbu Medical College | Asymptomatic Hyperuricemia | 01/23 | 01/23 | | |
NCT05706207: A Study of HB0030 Injection in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 36 | RoW | HB0030 injection, Recombinant Humanized Anti-TIGIT Monoclonal Antibody | Huabo Biopharm Co., Ltd., First Affiliated Hospital Bengbu Medical College | Advanced Solid Tumor | 09/23 | 09/23 | | |
NCT05939596: A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) |
|
|
| Active, not recruiting | 1 | 60 | RoW | SARS-CoV-2 Bivalent mRNA Vaccine, LVRNA021, Saline | AIM Vaccine Co., Ltd., First Affiliated Hospital Bengbu Medical College | SARS-CoV-2 | 09/23 | 08/24 | | |
NCT06144710: SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus |
|
|
| Recruiting | 1 | 48 | RoW | SG301 SC Injection, SG301 SC Placebo | Hangzhou Sumgen Biotech Co., Ltd. | Systemic Lupus Erythematosus (SLE) | 05/25 | 10/25 | | |
NCT06371326: A Study of ZT002 Injection in Participants With Overweight or Obesity |
|
|
| Enrolling by invitation | 1 | 28 | RoW | ZT002 Injection, Placebo | Beijing QL Biopharmaceutical Co.,Ltd | Overweight or Obesity | 08/24 | 09/24 | | |
NCT06360796: Study of Pharmacokinetics and Metabolism on [(14)C]ADC189 |
|
|
| Recruiting | 1 | 6 | RoW | [(14)C]ADC189 | Jiaxing AnDiCon Biotech Co.,Ltd | Pharmacokinetics, Metabolism | 06/24 | 07/24 | | |
GNC-035-103, NCT05160545: A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer |
|
|
| Recruiting | 1 | 29 | RoW | GNC-035 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Breast Cancer | 06/25 | 12/25 | | |
NCT05921006: Ascending Single-Dose and Multiple-Dose Study to Evaluate RJ4287 in Healthy Subjects |
|
|
| Recruiting | 1 | 98 | RoW | RJ4287, Placebo | Nanjing Ruijie Pharma Co., Ltd. | Drug Safety | 12/23 | 12/23 | | |
| Completed | 1 | 24 | RoW | cycle 1: treatment drug, cycle 1: reference drug, cycle 1: fasted, cycle 1: food, cycle 2: treatment drug, cycle 2: reference drug, cycle 2: fasted, cycle 2: food, cycle 3: treatment drug, cycle 3: reference drug, cycle 3: fasted, cycle 3: food | Shenzhen TargetRx, Inc., First Affiliated Hospital Bengbu Medical College | Non Small Cell Lung Cancer | 01/24 | 01/24 | | |
NCT05088070: Clinical Study of SPH3348 Tablets, a C-Met Inhibitor, in Patients with Advanced Solid Tumors |
|
|
| Completed | 1 | 40 | NA | SPH 3348 | Shanghai Pharmaceuticals Holding Co., Ltd | Solid Tumor | 07/23 | 07/23 | | |
NCT05684653: Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject |
|
|
| Recruiting | 1 | 34 | RoW | Orelabrutinib Tablets | Beijing InnoCare Pharma Tech Co., Ltd. | Hepatic Impairment | 12/23 | 12/23 | | |
NCT05271682: A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma |
|
|
| Recruiting | 1 | 40 | RoW | FHND6091 | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | Multiple Myeloma | 12/23 | 12/24 | | |
| Recruiting | 1 | 96 | US, RoW | GQ1001 | GeneQuantum Healthcare (Suzhou) Co., Ltd., Conjugate Light (Australia) Pty Ltd | HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor | 03/24 | 05/24 | | |
KN-8701, NCT04913285: A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors |
|
|
| Recruiting | 1 | 400 | Europe, US, RoW | KIN-2787, exarafenib, KIN-2787 and binimetinib, exarafenib and binimetinib | Pierre Fabre Medicament | Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma | 12/24 | 12/25 | | |
NCT05339685: A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors |
|
|
| Recruiting | 1 | 26 | RoW | BL-M02D1 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Breast Cancer | 12/24 | 12/24 | | |
NCT05245058: SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors |
|
|
| Recruiting | 1 | 150 | RoW | SPH5030 tablets | Shanghai Pharmaceuticals Holding Co., Ltd | HER2-positive Advanced Solid Tumors | 12/24 | 12/24 | | |
| Recruiting | 1 | 19 | RoW | TR64 | Tarapeutics Science Inc. | Advanced Solid Tumor | 08/26 | 12/26 | | |
NCT06589635: A Drug-Drug Interaction (DDI) Study of ADC189 With Itraconazole in Healthy, Adult Subjects |
|
|
| Recruiting | 1 | 16 | RoW | ADC-189 and Itraconazole, Part 1: Single dose of ADC-189; Part 2: Itraconazole with single dose of ADC-189 | Jiaxing AnDiCon Biotech Co.,Ltd | Healthy Adults | 09/24 | 12/24 | | |
NCT05673538: TT-00973-MS Tablets in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 40 | RoW | TT-00973-MS tablets treatment | TransThera Sciences (Nanjing), Inc. | Advanced Solid Tumor | 12/24 | 12/25 | | |
NCT06749236: A Study to Evaluate the Bioavailability of Two Specifications of Oral Deuremidevir Hydrobromide for Suspension |
|
|
| Not yet recruiting | 1 | 18 | RoW | test formulation(T) 200 mg deuteriumremidvir hydrobromide for suspension, reference formulation(R) 100 mg deuteriumremidvir hydrobromide for suspension | Vigonvita Life Sciences | Healthy Participants | 03/25 | 03/25 | | |
NCT05244551: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 85 | US, RoW | ABSK061 | Abbisko Therapeutics Co, Ltd | Solid Tumor | 04/25 | 04/25 | | |
NCT05574985: Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell) |
|
|
| Completed | N/A | 272 | RoW | Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell), Inactivated COVID-19 vaccine (Vero Cell) | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., First Affiliated Hospital Bengbu Medical College | COVID-19 | 10/22 | 03/23 | | |
NCT05547256: A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China |
|
|
| Active, not recruiting | N/A | 54 | RoW | COVID-19 Variant (Omicron BA.5) mRNA Vaccine Low dose, COVID-19 Variant (Omicron BA.5) mRNA Vaccine High dose, Placebo | AIM Vaccine Co., Ltd., Ningbo Rongan Biological Pharmaceutical Co. Ltd., First Affiliated Hospital Bengbu Medical College | SARS-CoV-2 | 12/22 | 03/24 | | |
NCT05550142: A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China |
|
|
| Active, not recruiting | N/A | 54 | RoW | SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose, SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine High dose, Placebo | AIM Vaccine Co., Ltd., Ningbo Rongan Biological Pharmaceutical Co. Ltd., First Affiliated Hospital Bengbu Medical College | SARS-CoV-2 | 12/22 | 03/24 | | |
NCT05547243: A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China |
|
|
| Active, not recruiting | N/A | 350 | RoW | SARS-CoV-2 mRNA Vaccine, Bivalent Low dose, SARS-CoV-2 mRNA Vaccine, Bivalent High dose, Placebo | AIM Vaccine Co., Ltd., Ningbo Rongan Biological Pharmaceutical Co. Ltd., First Affiliated Hospital Bengbu Medical College | SARS-CoV-2 | 12/22 | 03/24 | | |
NCT05549206: A Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in Chinese People |
|
|
| Not yet recruiting | N/A | 350 | NA | SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine low dose, SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine high dose, Placebo | AIM Vaccine Co., Ltd., Ningbo Rongan Biological Pharmaceutical Co. Ltd., First Affiliated Hospital Bengbu Medical College | SARS-CoV-2 | 04/23 | 04/24 | | |
NCT05745545: Clinical Trial of COVID-19 Vaccine（SARS-CoV-2 Variant(Omicron BA.5) mRNA Vaccine） in Participants Aged 18 Years and Over |
|
|
| Recruiting | N/A | 3200 | RoW | SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine, Saline solution | AIM Vaccine Co., Ltd., First Affiliated Hospital Bengbu Medical College, Ningbo Rongan Biological Pharmaceutical Co. Ltd. | SARS-CoV-2 | 09/23 | 11/23 | | |
| Wang, Zishu |
NCT03236649: The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects |
|
|
| Terminated | 3 | 89 | RoW | Icaritin, Sorafenib Tosylate Tablets | Beijing Shenogen Biomedical Co., Ltd, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Eastern Theater General Hospital,QinHuai District Medical Area, Peking University Cancer Hospital & Institute, Chinese PLA General Hospital, Beijing Hospital, General Hospital of Chinese Armed Police Forces, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Jinan Central Hospital, Linyi Cancer Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Nanfang Hospital of Southern Medical University, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Tianjin Medical University Cancer Institute and Hospital, The Fourth Hospital of Hebei Medical University, Hunan Cancer Hospital, The First Hospital of Jilin University, 307 Hospital of PLA, Fudan University, Henan Cancer Hospital, Jilin Provincial Tumor Hospital, First Affiliated Hospital of Harbin Medical University, First Affiliated Hospital Bengbu Medical College, The First Affiliated Hospital of Soochow University, Tongji Hospital, Beijing YouAn Hospital | Hepatocellular Carcinoma (HCC) | 02/22 | 02/22 | | |
NCT05088070: Clinical Study of SPH3348 Tablets, a C-Met Inhibitor, in Patients with Advanced Solid Tumors |
|
|
| Completed | 1 | 40 | NA | SPH 3348 | Shanghai Pharmaceuticals Holding Co., Ltd | Solid Tumor | 07/23 | 07/23 | | |
